New work from Roswell Park adds evidence that FDA-approved leukemia drug improves T cell quality and function Standard therapies prove ineffective for a third of patients with DLBCL Roswell Park team studying whether Bcl-2-inhibiting drug may enhance CAR T Underlying mechanism hinges on calcium signaling, scientists reveal About a third of patients with diffuse …
RNA sequencing identified how venetoclax influences the phenotypic and qualitative changes in CAR T cells
Share.